2.5 510(K) SUMMARY OF SAFETY AND EFFECTIVENESS

Date Summary Prepared	February 5, 2015		
Manufacturer/	Arthrex, Inc.		
Distributor/	1370 Creekside Boulevard		
Sponsor	Naples, FL 34108-1945 USA		
510(k) Contact	Laura Medlin		
	Regulatory Affairs		
	Arthrex, Inc.		
	1370 Creekside Boulevard		
	Naples, FL 34108-1945 USA		
	Telephone: 239/643.5553, ext. 72005		
	Fax: 239/598.5508		
	Email: Laura.Medlin@Arthrex.com		
Transla Maria			
Trade Name	Arthrex Distal Radius System		
Common Name	Plate, fixation, bone		
	Screw, fixation, bone		
Product Code,	HRS – Plate, Fixation, Bone		
Classification Name	HWC – Screw, Fixation, Bone		
CFR	21 CFR 888.3030: Single/multiple component metallic bone fixation appliances		
	and accessories		
	21 CFR 888.3040: Smooth or threaded metallic bone fixation fastener		
Dundinata Davina			
Predicate Device	K082300: DePuy Orthopaedics Anatomic Locking Plating System		
	K081546: DePuy Orthopaedics Small Bone Locking Plating System		
	K131474: Arthrex Distal Radius Plate System		
	K040907: Arthrex Small Fragment Plates and Screws		
Purpose of Submission	This traditional 510(k) premarket notification is submitted to obtain clearance for		
	the Arthrex Distal Radius System.		
Device Description	The Arthrex Distal Radius System is a family of implantable titanium plates and		
•	screws intended to be used for fixation of fractures, fusions, osteotomies and non-		
	unions of the radius, ulna, olecranon, metacarpal, metatarsal, and malleolus.		
	The subject plates are contoured and may be available in left and right		
	configurations, ranging in length from 25mm to 166mm and feature both locking		
	and non-locking holes.		
	The accompanying screws are solid, fully or partially threaded, and may be locking		
	or non-locking. The proposed screw offering subject of this application are 2.4mm		
	to 3.5mm in diameter and 8mm to 34mm in length and include the Arthrex Low		
	Profile Screws previously cleared under the auspices of K131474.		
Intended Use	The Arthrex Distal Radius System is intended for fixation of fractures, fusions,		
	osteotomies and non-unions of the radius, ulna, olecranon, metacarpal,		
	metatarsal, and malleolus.		
	A second included the second at the second s		
Substantial	The Arthrex Distal Radius System is substantially equivalent to the predicate		
Equivalence Summary	devices, in which the basic design features and intended uses are the same. Any		
	differences between the Arthrex Distal Radius System and the predicates are		
	considered minor and do not raise questions concerning safety and effectiveness.		
	The submitted mechanical testing data demonstrates that the bending strength of		
	the plates is substantially equivalent to that of the predicate devices.		
	Based on the indication for use, technological characteristics, and the summary of		
	i data submitted Arthrey Inc. has determined that the Arthrey Distri Madius		
	data submitted, Arthrex, Inc. has determined that the Arthrex Distal Radius System is substantially equivalent to currently marketed predicate devices.		

2.4 INDICATIONS FOR USE

DEPARTMENT OF HEALTH AND HUMAN SERVI		ICES	Form Approved: OMB No. 0910-0120
	Food and Drug Administration Indications for Use		Expiration Date: January 31, 2017 See PRA Statement below.
i10(k) Number (if known)			
rib(k) (Validee) (ir kilomi)	K143749		
Device Name			
arthrex Distal Radius System	m .		
	e) s System is intended for fixation of fr al, metatarsal, and malleolus.	actures, fusions, oster	tomies and non-unions of the radius,
			€
ype of Use (Select one or b			
· _	on Use (Part 21 CFR 801 Subpart D)	Over-The-Cour	ter Use (21 CFR 801 Subpart C)
M L LESCHPIII	View V		
	CONTINUE ON A SEPARA	ATE PAGE IF NEEDS	EO.
		f the Department Dade	tion Act of 1005
	s section applies only to requirements of	•	
*DO NOT S	SEND YOUR COMPLETED FORM TO	THE PRA STAFF EM	AL ADDRESS BELOW.
DO NOT S The burden time time to review ins and review the co	SEND YOUR COMPLETED FORM TO for this collection of information is estim structions, search existing data sources, ollection of information. Send comments in collection, including suggestions for re	THE PRA STAFF EMA nated to average 79 ho , gather and maintain to s regarding this burder aducing this burden, to	AIL ADDRESS BELOW. AITS per response, including the he data needed and complete estimate or any other aspect :
DO NOT S The burden time time to review ins and review the co	GEND YOUR COMPLETED FORM TO for this collection of information is estimatructions, search existing data sources, ollection of information. Send comments in collection, including suggestions for reDepartment of Healt Food and Drug Adm Office of Chief Inform Paperwork Reductio	THE PRA STAFF EM/ nated to average 79 ho , gather and maintain to a regarding this burder aducing this burden, to the and Human Services inistration mation Officer on Act (PRA) Staff	AIL ADDRESS BELOW. AITS per response, including the he data needed and complete estimate or any other aspect :
DO NOT S The burden time time to review ins and review the co of this information	SEND YOUR COMPLETED FORM TO for this collection of information is estimatructions, search existing data sources, collection of information. Send comments in collection, including suggestions for repeartment of Health Food and Drug Adm Office of Chief Information.	THE PRA STAFF EMI nated to average 79 ho , gather and maintain is regarding this burder educing this burden, to th and Human Services inistration metion Officer in Act (PRA) Staff gov rson is not required to	AIL ADDRESS BELOW. Aurs per response, including the he data needed and complete estimate or any other aspect :



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

April 3, 2015

Arthrex Inc. Ms. Laura Medlin Regulatory Affairs 1370 Creekside Boulevard Naples, Florida 34108-1945

Re: K143749

Trade/Device Name: Arthrex Distal Radius System

Regulation Number: 21 CFR 888.3030

Regulation Name: Single/multiple component metallic bone fixation appliances and

accessories

Regulatory Class: Class II Product Code: HRS, HWC Dated: February 5, 2015 Received: February 11, 2015

Dear Ms. Laura Medlin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Mark N. Melkerson -S

Mark N. Melkerson
Director
Division of Orthopedic Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure